Vaidehi S. Dedania, MD, considers the practical implications of data presented at AAO 2023 on the management of patients with age-related macular degeneration.
Dr Dedania remarks on the value of the post hoc analyses of TENAYA and LUCERNE in confirming the benefits of faricimab, suggesting its appropriate use even earlier in a treatment course. The results of the GALE and GATHER2 studies offer patients more data on the increasing treatment effects over time and the safety and efficacy of avacincaptad pegol. Dr Dedania concludes with noting the promise of novel research, including data on tyrosine kinase inhibitors, TIE pathway inhibitors, and gene therapy for wet AMD.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: AAO 2023: Clinical Insights From New Data on Age-Related Macular Degeneration - Medscape - Nov 27, 2023.